By Dean Seal
Qiagen has received clearance from U.S. regulators to market its gastrointestinal-illness test.
The Netherlands life-sciences and diagnostics company said Thursday that the Food and Drug Administration's clearance involves the QIAstat-Dx Gastrointestinal Panel 2 Mini B&V, which covers five causes of gastrointestinal illness that are recommended by the Infectious Diseases Society of America.
Among the illnesses are salmonella and norovirus, which is one of the most common causes of gastrointestinal infection and an important virus to target during the winter season.
The company plans to submit a second version of the panel, which will cover five common bacterial pathogens, to the FDA in the coming weeks.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
January 09, 2025 17:09 ET (22:09 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.